Survivin was identified as a prognostic marker in advanced NSCLC (HR = 1.93, 95% CI: 1.49–2.51), but not in early stages of the disease (HR = 1.97, 95% CI: 0.76–5.14). This evidence concerns the gene BIRC5 and non-small cell lung carcinoma.